← All trials
NCT06092957
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2023
- Primary completion
- Oct 30, 2029
- Completion date
- Oct 30, 2031
- First posted
- Oct 23, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 504
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Central South UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Xiamen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Shantou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.